Trial reportVirchows Archiv : an international journal of pathology2013
Histopathology of prostate tissue after vascular-targeted photodynamic therapy for localized prostate cancer.
Trial report in Virchows Archiv : an international journal of pathology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 47 citations in OpenAlex.
- Treatment-related changes in the prostate: past, present and future therapies.Histopathology · 2026Review
- Photodynamic therapy for the precise treatment of localized prostate cancer.Frontiers in oncology · 2025Review
- The role of reactive oxygen species in the transformation from prostatitis to prostate cancer: a review.Frontiers in immunology · 2025Review
- Real-Time and Delayed Imaging of Tissue and Effects of Prostate Tissue Ablation.Current urology reports · 2023Review
- Final Results of a Phase I Trial of WST-11 (TOOKAD Soluble) Vascular-targeted Photodynamic Therapy for Upper Tract Urothelial Carcinoma.The Journal of urology · 2023Article
- Vascular and Collagen Target: A Rational Approach to Hypertrophic Scar Management.Advances in wound care · 2023Review
- Trial watch: an update of clinical advances in photodynamic therapy and its immunoadjuvant properties for cancer treatment.Oncoimmunology · 2023Article
- Photodynamic therapy for prostate cancer: Recent advances, challenges and opportunities.Frontiers in oncology · 2022Review
- Neoadjuvant vascular-targeted photodynamic therapy improves survival and reduces recurrence and progression in a mouse model of urothelial cancer.Scientific reports · 2021Article
- Developments in Vascular-Targeted Photodynamic Therapy for Urologic Malignancies.Molecules (Basel, Switzerland) · 2020Review
- Focal therapy for localized prostate cancer in the era of routine multi-parametric MRI.Prostate cancer and prostatic diseases · 2020Review
- A promising anticancer drug: a photosensitizer based on the porphyrin skeleton.RSC medicinal chemistry · 2020Review
- Photodynamic therapy for prostate cancer: a systematic review and meta-analysis.Prostate international · 2019Review
- Effectiveness of the combination of vascular targeted photodynamic therapy and anti-cytotoxic T-lymphocyte-associated antigen 4 in a preclinical mouse model of urothelial carcinoma.International journal of urology : official journal of the Japanese Urological Association · 2019Article
- Surveillance after prostate focal therapy.World journal of urology · 2019Review
- Prostate cancer "super-active surveillance" era opened by vascular targeted photodynamic therapy.Research and reports in urology · 2019Review
- WST11 Vascular Targeted Photodynamic Therapy Effect Monitoring by Multispectral Optoacoustic Tomography (MSOT) in Mice.Theranostics · 2018Article
- Clinical development of photodynamic agents and therapeutic applications.Biomaterials research · 2018Review
- Photosensitizers in prostate cancer therapy.Oncotarget · 2017Review
- An update on focal therapy for prostate cancer.Nature reviews. Urology · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Low-risk prostate adenocarcinoma is classically managed either with active surveillance or radical therapy (such as external radiotherapy or radical prostatectomy), but both have significant side effects. Vascular-targeted photodynamic therapy (VTP) is a focal therapy proposed as an alternative approach for localized, low-volume, and low-Gleason score (≤6) carcinomas. We report histological modifications observed in prostate biopsies of 56 patients, performed 6 months after VTP using the photosensitizer TOOKAD® Soluble (WST11) and low-energy laser administered in the tumor area transperineally by optic fibers. In 53 patients, we observed sharply demarcated hyaline fibrotic scars, with or without rare atrophic glands, sometimes reduced to corpora amylacea surrounded by giant multinuclear macrophages. Mild chronic inflammation, hemosiderin, and coagulative necrosis were also observed. When residual cancer was present in a treated lobe (17 patients), it was always located outside the scar, most often close to the prostate capsule, and it showed no therapy-related modification. Histopathological interpretation of post-WST11 VTP prostate biopsies was straightforward, in contrast with that of prostate biopsies after radio or hormonal therapy, which introduces lesions difficult to interpret. VTP resulted in complete ablation of cancer in the targeted area.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.